AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14687173 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 10 mg once daily
Number of subjects: 18
Study 14687173 — intervention group
Group type: COMPARATOR
Intervention: Water only (baseline data)
Number of subjects: 18
Study 12002921 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced inhalational anaesthesia and prophylactic dolasetron (group I+D)
Number of subjects: 144
Study 12002921 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol TIVA and dolasetron (group T+D)
Number of subjects: 144
Study 12002921 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA alone (group T)
Number of subjects: 144
Study 9818008 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotropin (GH) 0.3 units/kg/day for 6 days before and after surgery
Number of subjects: 33
Study 9818008 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 days before and after surgery
Number of subjects: 33
Study 9818008 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo for 6 days before and GH (0.3 units/kg/day) for 6 days after surgery
Number of subjects: 33
Study 7528716 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuzhongping
Number of subjects: 46
Study 7528716 — intervention group
Group type: COMPARATOR
Intervention: Dextran-40
Number of subjects: 46
Study 2683921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (20 1-g capsules for 12 weeks)
Number of subjects: 38
Study 2683921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 38
Study 2683921 — intervention group
Group type: COMPARATOR
Intervention: Placebo (safflower oil) supplementation
Number of subjects: 38
Study 4174401 — intervention group
Group type: EXPERIMENTAL
Intervention: British gammaglobulin
Number of subjects: 87
Study 30326006 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) 400 mg to 800 mg 3 times a day for 8 weeks
Number of subjects: 18
Study 30326006 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin (PGB) 150 mg to 300 mg twice daily for 8 weeks
Number of subjects: 18
Study 30326006 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GBP vs PGB
Number of subjects: 18
Study 28389489 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Walking Training (IWT) supported by the smartphone-based InterWalk application for 8-12 weeks
Number of subjects: 246
Study 28389489 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Walking Training (IWT) with motivational support
Number of subjects: 246
Study 28389489 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Walking Training (IWT) without motivational support
Number of subjects: 246
Study 28389489 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 246
Study 28389489 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 246
Study 25107946 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mm tip fully irrigated ablation catheter (CF)
Number of subjects: 60
Study 25107946 — intervention group
Group type: COMPARATOR
Intervention: standard 3.5 mm tip ablation catheter with six distal irrigation channels (6C)
Number of subjects: 60
Study 23224298 — intervention group
Group type: EXPERIMENTAL
Intervention: COX‐2 inhibitor (Celecoxib)
Number of subjects: 23
Study 23224298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 23224298 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Celecoxib and placebo)
Number of subjects: 23
Study 22089305 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Number of subjects: 12
Study 22089305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18005368 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 50
Study 18005368 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 50
Study 17127538 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Naltrexone Therapy (BNT)
Number of subjects: 69
Study 17127538 — intervention group
Group type: COMPARATOR
Intervention: Compliance Enhancement (CE)
Number of subjects: 69
Study 12794092 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of predominantly lower limb, combined aerobic and resistance training
Number of subjects: 10
Study 12794092 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched healthy control subjects)
Number of subjects: 10
Study 11783256 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Traditional Chinese and Western medicine (TCM-WM)
Number of subjects: 0
Study 11783256 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 0
Study 8732376 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 41
Study 8732376 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 41
Study 8732376 — intervention group
Group type: COMPARATOR
Intervention: Both groups with TIMI 0 or 1 grade coronary patency
Number of subjects: 41
Study 8732376 — intervention group
Group type: COMPARATOR
Intervention: Both groups with TIMI 2 or 3 grade coronary flow
Number of subjects: 41
Study 2009146 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril (15 mg twice daily)
Number of subjects: 142
Study 2009146 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 mg daily, with potential doubling of dose if necessary)
Number of subjects: 142
Study 2009146 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril and Enalapril with addition of hydrochlorothiazide (25 mg daily if target not reached)
Number of subjects: 142
Study 2009146 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril and Enalapril
Number of subjects: 142
Study 7051958 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0
Study 7051958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31912678 — intervention group
Group type: EXPERIMENTAL
Intervention: ddPC (weekly paclitaxel and 3-weekly carboplatin)
Number of subjects: 73
Study 30564920 — intervention group
Group type: EXPERIMENTAL
Intervention: Taeniectomy pouch
Number of subjects: 180
Study 30564920 — intervention group
Group type: COMPARATOR
Intervention: Transverse coloplasty pouch
Number of subjects: 180
Study 28798999 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast β‐glucan and mannan oligosaccharide (GM)
Number of subjects: 6
Study 28798999 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginic acid (AC)
Number of subjects: 6
Study 28798999 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast nucleotides and RNA (NR)
Number of subjects: 6
Study 28798999 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus strains (BS)
Number of subjects: 6
Study 28798999 — intervention group
Group type: COMPARATOR
Intervention: High fish meal diet (C‐HF)
Number of subjects: 6
Study 28798999 — intervention group
Group type: COMPARATOR
Intervention: Basal low fish meal diet (C‐LF)
Number of subjects: 6
Study 28798999 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunostimulant-supplemented diets
Number of subjects: 6
Study 26230609 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health (SRH) rated as 'higher than others'
Number of subjects: 1476
Study 26230609 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health (SRH) rated as 'similar to others'
Number of subjects: 1476
Study 26230609 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health (SRH) rated as 'lower than others'
Number of subjects: 1476
Study 26230609 — intervention group
Group type: COMPARATOR
Intervention: Self-rated health (SRH)
Number of subjects: 1476
Study 25139479 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal cholecystectomy (TVC)
Number of subjects: 97
Study 25139479 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (CLC)
Number of subjects: 97
Study 21858678 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 42
Study 21858678 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.004% travoprost
Number of subjects: 42
Study 21858678 — intervention group
Group type: COMPARATOR
Intervention: travoprost
Number of subjects: 42
Study 19651668 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of physical activity measured by Caltrac (1st tertile +4.81% change; 2nd tertile +4.60% change; 3rd tertile +7.23% change; p-trend = 0.018)
Number of subjects: 111
Study 19651668 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of physical activity measured by Digiwalker (1st tertile +3.76% change; 2nd tertile +6.25% change; 3rd tertile +7.25% change; p-trend = 0.001)
Number of subjects: 111
Study 19651668 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of physical activity
Number of subjects: 111
Study 17065166 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of morphine (0.15 mg kg(‐1))
Number of subjects: 100
Study 17065166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15868556 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic fetal tracheal occlusion (TO)
Number of subjects: 24
Study 15868556 — intervention group
Group type: COMPARATOR
Intervention: Standard perinatal care (control)
Number of subjects: 24
Study 15868556 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at hospital discharge
Number of subjects: 24
Study 11796399 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination
Number of subjects: 31
Study 11796399 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonographic examination
Number of subjects: 31
Study 9020454 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet at ankle
Number of subjects: 50
Study 9020454 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic tourniquet at calf level
Number of subjects: 50
Study 7942653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical headgear/lower utility arch combination (CHG/LUA)
Number of subjects: 30
Study 7942653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical headgear alone (CHG)
Number of subjects: 30
Study 7942653 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 30
Study 7942653 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 3064717 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy (BCG and 5-FU)
Number of subjects: 322
Study 3064717 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (5-FU)
Number of subjects: 322
Study 3064717 — intervention group
Group type: COMPARATOR
Intervention: Control (no further treatment)
Number of subjects: 322
Study 31791675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (single subanesthetic-dose intravenous infusion)
Number of subjects: 188
Study 31791675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 31162102 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0
Study 31162102 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study 27923165 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient priming with Foley catheter
Number of subjects: 130
Study 27923165 — intervention group
Group type: COMPARATOR
Intervention: Inpatient priming with Foley catheter
Number of subjects: 130
Study 25539518 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based eDoctoring (n=48)
Number of subjects: 119
Study 25539518 — intervention group
Group type: COMPARATOR
Intervention: Small-group Doctoring (n=71)
Number of subjects: 119
Study 23974453 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine mediolateral episiotomy
Number of subjects: 171
Study 23974453 — intervention group
Group type: COMPARATOR
Intervention: Selective mediolateral episiotomy
Number of subjects: 171
Study 21435214 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 1968
Study 19242664 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 8057
Study 19242664 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 8057
Study 19242664 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 8057
Study 19242664 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg twice weekly)
Number of subjects: 8057
Study 19242664 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly)
Number of subjects: 8057
Study 19242664 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 8057
Study 17208413 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day plus celecoxib 400 mg/day (200 mg bid)
Number of subjects: 60
Study 17208413 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 6 mg/day plus placebo
Number of subjects: 60
Study 17208413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15124781 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer restorations
Number of subjects: 666
Study 15124781 — intervention group
Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 666
Study 11423506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (60, 120, or 180 mg)
Number of subjects: 15
Study 11423506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11423506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (60 mg)
Number of subjects: 15
Study 11423506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg)
Number of subjects: 15
Study 11423506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (180 mg)
Number of subjects: 15
Study 11423506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (higher doses)
Number of subjects: 15
Study 11229181 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (300 mg/day for 15 days)
Number of subjects: 30
Study 11229181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin E supplementation)
Number of subjects: 30
Study 8481587 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate (bisphosphonate)
Number of subjects: 380
Study 8481587 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone density measurement (2 standard deviations decrease)
Number of subjects: 380
Study 8481587 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quintile of bone density
Number of subjects: 380
Study 8481587 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of bone density
Number of subjects: 380
Study 8481587 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous use of bone density and prevalent fractures
Number of subjects: 380
Study 3320325 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin E supplementation
Number of subjects: 0
Study 3320325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2758752 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-patient lumbar radiculography with 10 ml iohexol (240 mgI/ml)
Number of subjects: 200
Study 2758752 — intervention group
Group type: COMPARATOR
Intervention: In-patient controls
Number of subjects: 200
Study 2758752 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-patient lumbar radiculography
Number of subjects: 200
Study 30036174 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational mobile application (game format)
Number of subjects: 43
Study 27726304 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day, multi-professional, simulation-based team training focusing on crew resource management (CRM)
Number of subjects: 28657
Study 27726304 — intervention group
Group type: COMPARATOR
Intervention: No team training (control)
Number of subjects: 28657
Study 25791185 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumba dance and nutrition education (n = 30)
Number of subjects: 59
Study 25791185 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (n = 29)
Number of subjects: 59
Study 24229826 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartinhaler Tracker electronic monitor
Number of subjects: 303
Study 21922978 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia grafts
Number of subjects: 38
Study 21922978 — intervention group
Group type: COMPARATOR
Intervention: Cartilage grafts
Number of subjects: 38
Study 19966701 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive, endovascular methods of treatment
Number of subjects: 6000
Study 16723553 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole at 400 mg twice daily on the first day and 200 mg twice daily on the second day
Number of subjects: 12
Study 16723553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole at 400 mg on the first day and 200 mg on the second day
Number of subjects: 12
Study 16723553 — intervention group
Group type: COMPARATOR
Intervention: Control (Ibuprofen alone)
Number of subjects: 12
Study 15596634 — intervention group
Group type: EXPERIMENTAL
Intervention: Hostility in high-risk women
Number of subjects: 3733
Study 15596634 — intervention group
Group type: EXPERIMENTAL
Intervention: Hostility in average-risk women
Number of subjects: 3733
Study 15596634 — intervention group
Group type: EXPERIMENTAL
Intervention: Hostility in high-risk men
Number of subjects: 3733
Study 15596634 — intervention group
Group type: EXPERIMENTAL
Intervention: Hostility in average-risk men
Number of subjects: 3733
Study 11150432 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with etoposide, bleomycin, and high or standard dose cisplatin
Number of subjects: 36
Study 11150432 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy and chemotherapy without tumor resection
Number of subjects: 36
Study 11150432 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection at diagnosis followed by chemotherapy
Number of subjects: 36
Study 11150432 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy followed by chemotherapy and post-chemotherapy tumor resection
Number of subjects: 36
Study 9048702 — intervention group
Group type: EXPERIMENTAL
Intervention: SCID diagnosis and a battery of life event questionnaires (Intervention group, N = 33)
Number of subjects: 63
Study 9048702 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostic program (Referent group, N = 30)
Number of subjects: 63
Study 9048702 — intervention group
Group type: EXPERIMENTAL
Intervention: SCID diagnosis and a battery of life event questionnaires (Intervention group)
Number of subjects: 63
Study 9048702 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of trauma (Intervention group)
Number of subjects: 63
Study 9048702 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychometric indices (Intervention group)
Number of subjects: 63
Study 8121966 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPT (alpha‐methyl‐para‐tyrosine)
Number of subjects: 14
Study 8121966 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine (active placebo)
Number of subjects: 14
Study 8121966 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs (fluoxetine, sertraline)
Number of subjects: 14
Study 3314790 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mw continuous wave HeNe laser treatment
Number of subjects: 81
Study 3314790 — intervention group
Group type: COMPARATOR
Intervention: Control group (laser off)
Number of subjects: 81
Study 30226133 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal follow-up
Number of subjects: 37
Study 30226133 — intervention group
Group type: COMPARATOR
Intervention: Conditional follow-up
Number of subjects: 37
Study 27138868 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed pegfilgrastim biosimilar
Number of subjects: 66
Study 27138868 — intervention group
Group type: COMPARATOR
Intervention: US-licensed pegfilgrastim reference product
Number of subjects: 66
Study 24506815 — intervention group
Group type: EXPERIMENTAL
Intervention: RRP (Retropubic Radical Prostatectomy)
Number of subjects: 339
Study 24506815 — intervention group
Group type: COMPARATOR
Intervention: LRP (Laparoscopic Radical Prostatectomy)
Number of subjects: 339
Study 24506815 — intervention group
Group type: EXPERIMENTAL
Intervention: RRP
Number of subjects: 339
Study 24506815 — intervention group
Group type: COMPARATOR
Intervention: LRP
Number of subjects: 339
Study 22564086 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit rules to guide anticipation
Number of subjects: 60
Study 22564086 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal cueing
Number of subjects: 60
Study 22564086 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit learning
Number of subjects: 60
Study 22564086 — intervention group
Group type: EXPERIMENTAL
Intervention: Color cueing
Number of subjects: 60
Study 22564086 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 60
Study 22564086 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 60
Study 20394252 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 40
Study 20394252 — intervention group
Group type: COMPARATOR
Intervention: 0.5% levobupivacaine with fentanyl 15 microg
Number of subjects: 40
Study 17626986 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (therapeutic doses throughout treatment)
Number of subjects: 91
Study 17626986 — intervention group
Group type: EXPERIMENTAL
Intervention: Parnaparin (therapeutic doses for the first month, then prophylactic phase at half dose)
Number of subjects: 91
Study 17626986 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (Nadroparin and Parnaparin)
Number of subjects: 91
Study 15793400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 2% lidocaine hydrochloride
Number of subjects: 16
Study 15793400 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 16
Study 12606735 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg adefovir dipivoxil
Number of subjects: 515
Study 12606735 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg adefovir dipivoxil
Number of subjects: 515
Study 12606735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 515
Study 10077797 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatiguing exercises of deltoid and rotator cuff
Number of subjects: 12
Study 10077797 — intervention group
Group type: COMPARATOR
Intervention: Rested state (before fatigue)
Number of subjects: 12
Study 8808185 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 9